# Benlysta (belimumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/belimumab

> The FDA approved Benlysta (belimumab), sponsored by GSK plc (GSK), on July 20, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Benlysta (belimumab) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Lung Diseases, Interstitial](https://sec-api.dev/indications/lung-diseases-interstitial), Systemic Sclerosis Associated Interstitial Lung Disease, [Connective Tissue Diseases](https://sec-api.dev/indications/connective-tissue-diseases) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### July 20, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761043 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170720, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22

### December 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761043 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20201216, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22

### February 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761043 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22

### May 16, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761043 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20240516, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22

### June 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761043 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05878717 (A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05878717

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lung Diseases, Interstitial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06572384 (A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06572384

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05878717 (A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05878717

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lung Diseases, Interstitial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06572384 (A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06572384

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Connective Tissue Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06716606 (A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06716606

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Connective Tissue Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06716606 (A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06716606

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/belimumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Benlysta (belimumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/belimumab

```bibtex
@misc{secapidev_pdufa_belimumab_20261116,
  title        = {Benlysta (belimumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/belimumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_belimumab_20261116","title":"Benlysta (belimumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/belimumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
